Loading quotes...

Forecast

The analysts' average price target is €58.09 (+2,271.02%). The median is €37.08 (+1,413.47%).

Buy	4
Hold	14
Sell	2

News Go to news feed

Tilray Brands (ex Aphria) raises quarterly revenue to USD 257.2 million (+22.7%)

Tilray Brands (ex Aphria) reported for the quarter ended August 31, 2026 a revenue increase of 22.74% to USD 257.2 million, compared with USD 209.5 million a year earlier. The earnings figure was released on October 8, 2026. » More on finanzen.net
Tilray invests £50m in BrewDog to improve beers, pubs and working conditions

Tilray, which bought BrewDog in March for £33m after the brewer entered administration, is investing more than £50m to improve beer quality, reopen and upgrade selected bars, raise pay and improve working conditions. The company is upgrading the Aberdeenshire brewery, launching new beers, introducing US craft lines into BrewDog venues and considering further UK craft acquisitions. Administrators said creditors will not be repaid in full and crowdfunding shares were rendered worthless, though some investor benefits and supplier continuity have been maintained. » More on theguardian.com
Tilray positioned to benefit if Trump advances marijuana rescheduling

A federal appeals court refused to pause the Biden administration's move to consider broader rescheduling of marijuana, keeping alive a proposal to reclassify cannabis to Schedule III. Schedule III would not legalize recreational use or interstate commerce but could ease research and expand medical opportunities that would help Tilray's international medical cannabis business. Tilray reported record fiscal 2026 revenue, sharply improved cash flow and near-elimination of net debt, and management sees U.S. rescheduling as a future growth opportunity. Legal challenges and timing remain uncertain, so potential investors should view rescheduling as upside rather than a guaranteed catalyst. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Tilray has already paid €0.10 in dividends. The last payout was in June 2022.

Financials

In the last quarter, Tilray had revenue of €221.35m and net profit of -€37.13m

(EUR)	August 2026	YoY
Revenue	221.35m	23.51%
Gross profit	66.72m	35.72%
Net profit	-37.13m	13,382.06%
EBITDA	-11.35m	161.77%

Fundamentals

Metric	Value
Market capitalization	€264.29m
Number of shares	111.83m
52-week high/low	€14.03 - €2.35
Dividends	No
Beta	1.92
P/E ratio	-1.89
PEG ratio	-0.02
P/B ratio	0.22
P/S ratio	0.31

Company profile

Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. It operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. The company provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. It offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. The company operates Tilray Medical, a medical platform that provides GMP-certified flowers, oils, vapes, edibles, and topicals. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Tilray, Inc. Tilray Brands Inc. was incorporated in 2018 and is headquartered in New York, New York.